XML 31 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income Taxes (Tables)
 12 Months Ended
Feb. 29, 2016
Income Tax Disclosure [Abstract]  
Schedule of Components of Income Tax Expense (Benefit)
A summary of the provision (benefit) for income taxes, all federal, is as follows:
 
2016
 
2015
Current
$
573,408

 
$
(163,241
)
Deferred (2016 restated)
(3,880,880
)
 
—

 
$
(3,307,472
)
 
$
(163,241
)
Schedule of Effective Income Tax Rate Reconciliation
A reconciliation between the Company’s effective tax rate and the statutory tax rate for the years ended February 29, 2016 and February 28, 2015 follows:
 
2016
 
2015
 
Total
 
Percent
 
Total
 
Percent
Statutory federal rate
$
1,443,409

 
34.00
 %
 
$
337,744

 
35.00
 %
Amount not subject to corporate income taxes
(285,024
)
 
(6.71
)%
 
(260,993
)
 
(27.05
)%
Permanent items
2,450

 
0.06
 %
 
—

 
—
 %
Pass-through tax credits
(46,324
)
 
(1.09
)%
 
(436,360
)
 
(45.22
)%
Adjustments to estimated taxable income of equity method investee
114,487

 
2.70
 %
 
(612,548
)
 
(63.48
)%
Change in valuation allowance (2016 restated)
(4,536,470
)
 
(106.86
)%
 
808,916

 
83.83
 %
Tax expense (benefit) at effective rate (2016 restated)
$
(3,307,472
)
 
(77.90
)%
 
$
(163,241
)
 
(16.92
)%
Schedule of Deferred Tax Assets and Liabilities
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used to determine taxable income for income tax reporting purposes. The following table presents the significant components of the non-current deferred tax assets (liabilities) of the Company and its consolidated subsidiaries related to its investments in Eldorado and Mesquite as of February 29, 2016 and 2015.
 
2016
 
2015
Tax credit carryforwards
$
—

 
$
436,360

Basis difference for marketable securities (2016 restated)
(1,923,740
)
 
5,057,227

Basis difference in equity method investee (2016 restated)
517,795

 
875,819

Acquisition costs
152,591

 
157,079

Contributions limitation and carryforward
—

 
106,029

Net operating loss carryforward
—

 
191,562

Subtotal
(1,253,354
)
 
6,824,076

Less: valuation allowance
—

 
(6,824,076
)
Net deferred tax liability
$
(1,253,354
)
 
$
—